Skip to content
Alligator Bioscience

Alligator Bioscience

sv
  • About Alligator
    • Board of directors
    • Management
    • Collaborations and partnerships
    • Career
  • Research & development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • ATOR-1015
      • ATOR-1017
      • ALG.APV-527
      • Research projects
    • Scientific publications
    • Technology platform
      • ALLIGATOR-FAB™
      • ALLIGATOR-GOLD®
      • FIND®
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and shareholders
    • Analysts
    • Preferential rights issue 2021
    • IPO
    • Financial reports
      • Annual reports
      • Interim reports
    • Calendar
    • Presentations
    • Subscribe
  • News
    • Press releases
    • Frontier – A magazine about Alligator
    • Subscribe
  • Contact
  • SV

  • Tumor-directed immunotherapy of cancer

Latest News

  • 26 Feb 2021 – Change in number of shares and votes in Alligator Bioscience AB
  • 26 Feb 2021 – Alligator Bioscience AB: Year-end Report January-December 2020
  • 23 Feb 2021 – Alligator Bioscience AB: Last day of trading in paid subscription shares (Sw. BTA)
  • 27 Jan 2021 – Alligator Bioscience’s rights issue oversubscribed
More news

Calendar

  • 9 Mar 2021 — 10 Mar 2021 ‐ H.C. Wainwright Global Life Sciences Conference
  • 17 Mar 2021 ‐ Tumor Microenvironment Conference
  • 29 Mar 2021 — 1 Apr 2021 ‐ Festival of Biologics
  • 7 Apr 2021 — 8 Apr 2021 ‐ Solebury Trout European Biotech Investor Days 2021
  • 20 Apr 2021 — 23 Apr 2021 ‐ NLSDays 2021

Year-end Report January-December 2020

CEO Per Norlén and CFO Marie Svensson presents the Year-end Report 2020. Listen to the presentation here.

Read the report here.

About

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase II studies.

Links

  • About Alligator
  • Research and development
  • Corporate governance
  • Investors
  • News
  • Contact
  • Privacy policy

Contact

Alligator Bioscience AB
Medicon Village
Scheelevägen 2
SE-223 81 Lund
Sweden

Phone: + 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com

Subscribe

Subscribe to get our pressreleases by email.

SUBSCRIBE

Alligator Bioscience

© Copyright 2018 - Alligator Bioscience AB

We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.I agreeI do not agree